Clinical Trials › NCT07207148
Recruiting
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
Sponsored by Northwestern University
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 100
Target enrollment
1
U.S. states
Nov 2025
Start date
Aug 2028
Expected completion
Interventions / Treatments
GLP-1Ocrelizumab (US)
Conditions studied
Multiple Sclerosis
Where this trial is running (1 site)
Illinois1 site
Chicago
Participating MS centers on MS Buddy (1)
MS centers in Illinois
Compare treatment centers near a trial site by center type, providers and trials.
View Illinois centersThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.